{
    "type": "VariantTherapeuticResponseProposition",
    "predicate": "sensitivity",
    "description": "Treatment of adult and pediatric patients 12 years of age and older with locally advanced or metastatic differentiated thyroid cancer (DTC) that has progressed following prior VEGFR-targeted therapy and who are radioactive iodine-refractory or ineligible",
    "geneContextQualifier": "KDR",
    "objectTherapeutic": "Cabozantinib [Cabometyx]"
}